{"pmid":32355638,"pmcid":"PMC7192087","title":"Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system.","text":["Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system.","Toxicol Rep","Farsalinos, Konstantinos","Niaura, Raymond","Le Houezec, Jacques","Barbouni, Anastasia","Tsatsakis, Aristidis","Kouretas, Dimitrios","Vantarakis, Apostolos","Poulas, Konstantinos","32355638"],"journal":"Toxicol Rep","authors":["Farsalinos, Konstantinos","Niaura, Raymond","Le Houezec, Jacques","Barbouni, Anastasia","Tsatsakis, Aristidis","Kouretas, Dimitrios","Vantarakis, Apostolos","Poulas, Konstantinos"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32355638","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.toxrep.2020.04.012","e_drugs":["Nicotine"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138495148621824,"score":9.490897,"similar":[{"pmid":32444400,"title":"COVID-19 and the nicotinic cholinergic system.","text":["COVID-19 and the nicotinic cholinergic system.","Eur Respir J","Farsalinos, Konstantinos","Angelopoulou, Athina","Alexandris, Nikos","Poulas, Konstantinos","32444400"],"journal":"Eur Respir J","authors":["Farsalinos, Konstantinos","Angelopoulou, Athina","Alexandris, Nikos","Poulas, Konstantinos"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32444400","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1183/13993003.01589-2020","topics":["Mechanism"],"weight":1,"_version_":1667600475774517248,"score":123.5676},{"pmid":32350104,"pmcid":"PMC7191112","title":"COVID-19 and Nicotine as a Mediator of ACE-2.","text":["COVID-19 and Nicotine as a Mediator of ACE-2.","Eur Respir J","Leung, Janice M","Yang, Chen Xi","Sin, Don D","32350104"],"journal":"Eur Respir J","authors":["Leung, Janice M","Yang, Chen Xi","Sin, Don D"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32350104","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1183/13993003.01261-2020","e_drugs":["Nicotine"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138495637258241,"score":78.71664},{"pmid":32341101,"title":"COVID-19 and Smoking. Is Nicotine the Hidden Link?","text":["COVID-19 and Smoking. Is Nicotine the Hidden Link?","Eur Respir J","Russo, Patrizia","Bonassi, Stefano","Giacconi, Robertina","Malavolta, Marco","Tomino, Carlo","Maggi, Fabrizio","32341101"],"journal":"Eur Respir J","authors":["Russo, Patrizia","Bonassi, Stefano","Giacconi, Robertina","Malavolta, Marco","Tomino, Carlo","Maggi, Fabrizio"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32341101","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1183/13993003.01116-2020","e_drugs":["Nicotine"],"topics":["Mechanism"],"weight":1,"_version_":1666138495855362048,"score":69.545074},{"pmid":32189428,"title":"Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population?","text":["Is nicotine exposure linked to cardiopulmonary vulnerability to COVID-19 in the general population?","The recent emergence of COVID-19 has resulted in a worldwide crisis, with large populations locked down and transportation links severed. While approximately 80% of infected individuals have minimal symptoms, around 15-20% need to be hospitalized, greatly stressing global healthcare systems. As of March 10, the death rate appears to be about 3.4%, although this number is highly stratified among different populations. Here, we focus on those individuals who have been exposed to nicotine prior to their exposure to the virus. We predict that these individuals are 'primed' to be at higher risk because nicotine can directly impact the putative receptor for the virus (ACE2) and lead to deleterious signaling in lung epithelial cells.","FEBS J","Olds, James L","Kabbani, Nadine","32189428"],"abstract":["The recent emergence of COVID-19 has resulted in a worldwide crisis, with large populations locked down and transportation links severed. While approximately 80% of infected individuals have minimal symptoms, around 15-20% need to be hospitalized, greatly stressing global healthcare systems. As of March 10, the death rate appears to be about 3.4%, although this number is highly stratified among different populations. Here, we focus on those individuals who have been exposed to nicotine prior to their exposure to the virus. We predict that these individuals are 'primed' to be at higher risk because nicotine can directly impact the putative receptor for the virus (ACE2) and lead to deleterious signaling in lung epithelial cells."],"journal":"FEBS J","authors":["Olds, James L","Kabbani, Nadine"],"date":"2020-03-20T11:00:00Z","year":2020,"_id":"32189428","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1111/febs.15303","keywords":["addiction","infectious disease","pandemic","public health","tobacco"],"e_drugs":["Nicotine"],"topics":["Mechanism"],"weight":1,"_version_":1666138490570539009,"score":60.848026},{"pmid":32470789,"title":"Survival of COVID-19 patients requires precise immune regulation: The hypothetical immunoprotective role of nicotinic agonists.","text":["Survival of COVID-19 patients requires precise immune regulation: The hypothetical immunoprotective role of nicotinic agonists.","recent studies have provided novel evidence regarding the effect of nicotine agonists on the prevention or modulation of cytokines storm and reduction of infection. In this study we tried to attempt to address these issues from a therapeutic perspective of nicotine agonists in this manner and we describe one of the most challenging theories of immunotherapy in coronavirus-19 (COVID-19). The analysis of the proposed mechanism goes beyond the physiological consequences of a way to design new strategies to provide anti-inflammatory drugs.","Med Hypotheses","Allahverdi Khani, M","SalehiRad, M","Darbeheshti, S","Motaghinejad, M","32470789"],"abstract":["recent studies have provided novel evidence regarding the effect of nicotine agonists on the prevention or modulation of cytokines storm and reduction of infection. In this study we tried to attempt to address these issues from a therapeutic perspective of nicotine agonists in this manner and we describe one of the most challenging theories of immunotherapy in coronavirus-19 (COVID-19). The analysis of the proposed mechanism goes beyond the physiological consequences of a way to design new strategies to provide anti-inflammatory drugs."],"journal":"Med Hypotheses","authors":["Allahverdi Khani, M","SalehiRad, M","Darbeheshti, S","Motaghinejad, M"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470789","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.mehy.2020.109871","keywords":["covid-19","immunotherapy","nicotinic agonist"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668167110006669312,"score":58.142723}]}